AKTX 8-K: press release on $2.5M registered direct offering

Rhea-AI Filing Summary

Akari Therapeutics (AKTX) furnished an 8-K announcing a $2.5 million registered direct offering. The company disclosed, under Item 7.01 (Regulation FD), that it issued a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.” The press release is included as an exhibit and the furnished information is not deemed filed under the Exchange Act.

Akari’s American Depositary Shares, each representing 2,000 ordinary shares, trade on Nasdaq under the symbol AKTX. The filing lists the date of the earliest event as October 15, 2025.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001541157 0001541157 2025-10-15 2025-10-15 0001541157 AKTX:AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember 2025-10-15 2025-10-15 0001541157 AKTX:OrdinarySharesParValue0.0001PerShareMember 2025-10-15 2025-10-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2025

AKARI THERAPEUTICS, PLC

(Exact Name of Registrant as Specified in Charter)

England and Wales		001-36288		98-1034922
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

22 Boston Wharf Road FL 7

Boston, MA 02210

(Address, including zip code, of Principal Executive Offices)

Registrant’s telephone number, including area code: (929) 274-7510

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered
American Depository Shares, each representing 2000 Ordinary Shares		AKTX		The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share*		N/A		The Nasdaq Stock Market LLC

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 15, 2025, Akari Therapeutics, Plc (the “Company”) issued a press release announcing titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering”. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information reported under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Document
10.1		Press Release dated October 15, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Akari Therapeutics, Plc
Date: October 15, 2025	By:	/s/ Abizer Gaslightwala
	Name:	Abizer Gaslightwala
	Title:	Chief Executive Officer

FAQ

What did Akari Therapeutics (AKTX) disclose in this 8-K?

The company furnished a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.”

Under which item was the information provided in the 8-K for AKTX?

Item 7.01, Regulation FD Disclosure.

Is the furnished information considered filed for liability purposes?

No. The information is furnished and not deemed filed under the Exchange Act or subject to Section 18 liabilities.

What exhibit accompanies the 8-K for AKTX?

An exhibit containing the press release dated October 15, 2025 is included.

What is AKTX’s listing and security structure noted in the filing?

American Depositary Shares, each representing 2,000 ordinary shares, trade on The Nasdaq Stock Market under AKTX.

What is the earliest event date in the 8-K?

October 15, 2025.